Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Corcept unveils promising survival data from phase 2 ALS fail
Corcept has tried to cast its recent phase 2 amyotrophic lateral sclerosis failure in a more flattering light by pointing to promising survival data.
James Waldron
Jun 5, 2025 8:21am
Vigil's rare brain disease drug flunks phase 2 study
Jun 4, 2025 9:45am
Sanofi's IL-33 drug fails COPD study
May 30, 2025 5:30am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
Prothena reburies drug after 2nd swing at rare disease misses
May 27, 2025 3:33am
Applied's rare disease drug suffers another phase 3 failure
May 19, 2025 7:20am
